Efficacy and safety of insomnia pharmacotherapies: Convergent evidence from Bayesian network meta-regression and FAERS-based disproportionality analysis.

Researchers compared common sleep medications to help doctors choose the best treatments for different types of insomnia. The study analyzed 15 clinical trials involving 2,408 patients who took various medications including newer dual orexin receptor antagonists (DORAs), benzodiazepines, Z-drugs, and melatonin. The researchers examined how well these drugs helped people fall asleep, stay asleep, and sleep longer, while also reviewing safety reports from real-world use.

The findings showed that daridorexant 25 mg was particularly effective for people who wake up frequently during the night or don't get enough total sleep time. Lemborexant 10 mg worked well for those who struggle to fall asleep initially and also helped improve overall sleep efficiency. Zolpidem 10 mg was also effective for sleep onset problems. Interestingly, melatonin 6 mg showed benefits primarily when used for 10-40 weeks rather than short-term.

Regarding safety, all medications showed some nervous system side effects, but the severity varied. Daridorexant had lower rates of severe breathing problems compared to some other options. The study emphasizes that medication choice should depend on your specific sleep problem—whether you have trouble falling asleep, staying asleep, or both.

While this research focused on pharmaceutical options, many patients with insomnia find acupuncture helpful as a complementary or alternative approach, particularly for those seeking non-medication strategies or experiencing medication side effects. If considering acupuncture for sleep issues, seek a licensed acupuncturist with experience treating insomnia.

This Bayesian network meta-regression analyzed 15 RCTs (n=2,408) comparing insomnia pharmacotherapies, with FAERS database pharmacovigilance analysis. For wake after sleep onset (WASO), daridorexant 25 mg/d demonstrated superior efficacy (SMD=-0.957, 95% CI: -1.436 to -0.479) compared to placebo, with lemborexant 10 mg/d (SMD=-0.624) and 5 mg/d (SMD=-0.612) also showing significant benefits. Melatonin 6 mg/d showed a "time window" of efficacy between weeks 10-40 when adjusted for follow-up period. Safety analysis revealed nervous system disorder signals for DORAs and doxepin. Daridorexant showed significantly lower severe dyspnea rates versus suvorexant and lemborexant (OR=0.256, 95% CI: 0.096-0.678). Clinical algorithm suggests daridorexant 25 mg/d for sleep maintenance insomnia, lemborexant 10 mg/d or zolpidem 10 mg/d for sleep onset difficulties. Practitioners should consider insomnia subtype and individual safety profiles when recommending conventional pharmacotherapy, recognizing that patients may benefit from adjunctive non-pharmacological interventions including acupuncture.